Therapeutic Monoclonal Antibodies for COVID-19 Management: an Update

Document Type


Publication Date



COVID-19, Sars-cov-2, Monoclonal Antibody, Casirivimab, Bamlanivimab, Imdevimab, Etesevimab, Tixagevimab with Cilgavimab, Bebtelovimab, Clinical Trialre, Purposed Mabs

Digital Object Identifier (DOI)


Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has affected more than 529 million people, and today the world is facing different mutant strains of the virus, leading to increased morbidity rates, fatality rates, and surfacing re-infections. Various therapies, such as prophylactic treatments, repurposed drug treatments, convalescent plasma, and polyclonal antibody therapy have been developed to help combat the coronavirus disease 2019 (COVID-19).

Area covered: This review article provides insights into the basic aspects of monoclonal antibodies (mAbs) for the therapy of COVID-19, as well as its advancement in terms of clinical trial and current approval status.

Expert opinion: Monoclonal antibodies represents the most effective and viable therapy and/or prophylaxis option against COVID-19, and have shown a reduction of the viral load, as well as lowering hospitalizations and death rates. In different countries, various mAbs are undergoing different phases of clinical trials, with a few of them having entered phases III and IV. Due to the soaring number of cases worldwide, the FDA has given emergency approval for the mAb combinations bamlanivimab with etesevimab and casirivimab with imdevimab.

Was this content written or created while at USF?


Citation / Publisher Attribution

Expert Opinion on Biological Therapy, v. 22, issue 6, p. 763-780